ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ABOS Acumen Pharmaceuticals Inc

3,25
0,03 (0,93%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Acumen Pharmaceuticals Inc ABOS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,03 0,93% 3,25 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
3,24 3,145 3,37 3,25 3,22
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.4.202414:00GLOBEAcumen Pharmaceuticals Presents First Comprehensive Clinical..
04.4.202414:00GLOBEAcumen Pharmaceuticals Collaborates with Lonza to Advance..
26.3.202412:00GLOBEAcumen Pharmaceuticals Reports Financial Results for the..
21.3.202413:00GLOBEAcumen Pharmaceuticals to Present Deeper Insights, Including..
19.3.202421:00GLOBEAcumen Pharmaceuticals to Report Fourth Quarter and Year-End..
12.3.202421:00GLOBEAcumen Pharmaceuticals to Participate in the Stifel 2024 CNS..
08.3.202414:50GLOBEAcumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid..
21.2.202414:00GLOBEAcumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid..
14.2.202414:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.2.202423:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
01.2.202413:16EDGAR2Form 8-K - Current report
01.2.202413:00GLOBEAcumen Pharmaceuticals Appoints Dr. James Doherty as..
20.1.202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202401:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:36EDGAR2Form 144 - Report of proposed sale of securities
19.1.202422:35EDGAR2Form 144 - Report of proposed sale of securities
18.1.202422:29EDGAR2Form 144 - Report of proposed sale of securities
18.1.202422:28EDGAR2Form 144 - Report of proposed sale of securities
18.1.202422:27EDGAR2Form 144 - Report of proposed sale of securities
12.1.202414:42EDGAR2Form 8-K - Current report
08.1.202414:33EDGAR2Form 8-K - Current report
04.1.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:15GLOBEAcumen Pharmaceuticals to Present at the 42nd Annual J.P...
04.12.202313:45EDGAR2Form 8-K - Current report
13.11.202323:10EDGAR2Form 8-K - Current report
13.11.202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202313:20EDGAR2Form 8-K - Current report
13.11.202313:00GLOBEAcumen Pharmaceuticals Reports Third Quarter 2023 Financial..
07.11.202322:01GLOBEAcumen Pharmaceuticals to Participate in the Stifel..
06.11.202322:01GLOBEAcumen Pharmaceuticals to Report Third Quarter Financial..
06.11.202313:30GLOBEAcumen Pharmaceuticals, Inc. and Halozyme Enter Global..
02.11.202321:00GLOBEAcumen Pharmaceuticals to Participate in the UBS Biopharma..
27.10.202315:25GLOBEAcumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates..
04.10.202314:00GLOBEAcumen Pharmaceuticals to Present Deeper Insights from..
19.9.202322:00GLOBEAcumen Pharmaceuticals to Participate in the Cantor Global..
06.9.202322:00GLOBEAcumen Pharmaceuticals to Participate in the H.C. Wainwright..
19.8.202300:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.8.202317:46EDGAR2Form 144 - Report of proposed sale of securities
08.8.202322:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202313:33EDGAR2Form 8-K - Current report
08.8.202313:00GLOBEAcumen Pharmaceuticals Reports Second Quarter 2023 Financial..
01.8.202322:00GLOBEAcumen Pharmaceuticals to Report Second Quarter Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock